Live Breaking News & Updates on Diamir Biosciences

Stay updated with breaking news from Diamir biosciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Interpace Biosciences Announces First Quarter 2021 Financial and Business Results


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Interpace Biosciences Announces First Quarter 2021 Financial and Business Results
Interpace Biosciences, Inc.May 11, 2021 GMT
 

Q1 Revenue of $9.8 Million is Company’s Highest as Combined Molecular Diagnostics and Pharma Services Business
 
 
 
ADVERTISEMENT
PARSIPPANY, NJ, May 11, 2021 (GLOBE NEWSWIRE) Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended March 31, 2021 and provided a business and financial update.
“We are very pleased with our first quarter operating results which are on track and in accordance with our growth, restructuring and reprioritization plan,” said President and CEO Thomas Burnell. “As we progress further into 2021, we expect to build on this momentum and will be focused on opportunities related to expanded pri ....

United States , New Jersey , North Carolina , Interpace Biosciences , Tom Freeburg , Interpace Bioscience , Thomas Burnell , Guggenheim Securities , Company Annual Report On Form , Interpace Biosciences Inc , Laboratory Analysis , Pharma Services Business , Interpace Pharma Solutions , University Of New Jersey , Securities Exchange , Xifin Inc , Combined Molecular Diagnostics , Pharma Services , Exceed Full Year , First Quarter , Continuing Operations , Sales Outstanding , Fourth Quarter , Blue Cross Shield , State University , Massachusetts General Hospital ,

Interpace Biosciences Announces Divestiture of New Haven CLIA lab to DiamiR


Interpace Biosciences Announces Divestiture of New Haven CLIA lab to DiamiR
March 17, 2021 07:30 ET
| Source:
Interpace Biosciences, Inc.
Interpace Biosciences, Inc.
Part of Company’s Site Consolidation and Cost Savings Measures
Parsippany, NJ, March 17, 2021 (GLOBE NEWSWIRE) Interpace Biosciences, Inc. (OTC: IDXG) announced today that it has entered into a definitive agreement to sell its New Haven CT CLIA certified, CAP accredited laboratory to DiamiR Biosciences, Corp. (DiamiR). This sale is in line with previously announced restructuring and cost reduction initiatives announced by Interpace. Under this agreement, DiamiR will provide overflow lab testing in support of the Company’s molecular thyroid testing products at its main laboratory in Pittsburgh, PA. DiamiR will also support specific Interpace assay development and validation services on behalf of the Company for the next three quarters. Subject to specific ter ....

Megan Paul , Interpace Bioscience , Interpace Biopharma , Tom Burnell , Interpace Biosciences Inc , Haven Laboratory , Securities Exchange , Part Of Company Site Consolidation , Edison Group , Site Consolidation , Cost Savings , New Haven , Diamir Biosciences , New Haven Laboratory , Interpace Biosciences , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Best Market , Annual Report , Current Reports , Quarterly Reports , Otc Markets Idxg , Otc Idxg , New Haven Clia Lab To Diamir , Cost Savings Measures ,